UNSPSC 51143501: Carbidopa/entacapone/levodopa

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CN500. This VA Drug Class (CN500) classifies this compound as belonging to the group ANTIPARKINSON AGENTS.

UNSPSC 51143501 Carbidopa/entacapone/levodopa is a Commodity code that in state and local procurement practice covers specific pharmaceutical formulations used in Parkinson's disease management, though the recent opportunity record shows activity misaligned with this code's nominal scope. The source contains no recent solicitations for carbidopa/entacapone/levodopa itself. Instead, the single posted opportunity tagged to this code involves procurement of naloxone and safe drug deactivation systems—opioid-reversal medications and harm-reduction equipment unrelated to the code's stated pharmaceutical product. This mismatch suggests either a cataloging error in the source data or a deviation in how the issuing body applied the UNSPSC taxonomy.

Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding, with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The response deadline was July 26, 2023—a date that post-dates the posting by only 26 days and appears to contain a year discrepancy in the source record. Vendors must include all shipping and delivery costs, maintain workers' compensation and commercial general liability insurance, comply with E-Verify requirements, and meet federal regulations if FEMA funding applies. The contract offers an initial two-year term with a one-year renewal option. Beyond this single Seminole County solicitation, the code shows no recent activity in the state and local market.